Zhongshan Hospital,Fudan University(Xiamen Branch)
Welcome,         Profile    Billing    Logout  
 53 Trials 
62 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Xin Shelley
NCT03908138: RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

Recruiting
4
120
RoW
RDD, RDD group, VDD, VDD group
Shandong Provincial Hospital
Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety
12/21
12/22
NCT06398834: Esketamine and Butorphanol for Post-Lobectomy Pain

Completed
4
223
RoW
Esketamine, S-Ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, L-Ketamine, (-)-Ketamine, Butorphanol, Butorphanol Tartrate, Moradol, Stadol, Torbugesic, Apo-Butorphanol, Dolorex
Second People's Hospital of Hefei City, Tongji Hospital
Esketamine, Pain, Post-thoracotomy Pain Syndrome, Thoracic Diseases
10/23
01/24
NCT04738955: Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors

Recruiting
4
230
RoW
Micafungin Sodium
Shandong Provincial Hospital
Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease
01/23
10/23
NCT05181475: Long-term Efficacy and Safety Study of GV-971

Active, not recruiting
4
800
RoW
Sodium Oligomannate Capsules (GV-971)
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease
01/25
06/25
NCT03328234: Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03

Recruiting
3
2
RoW
SIB-IMRT, Paclitaxel, Platinum-Based Drug, Involved Field Irradiation (IFI)
Chinese Academy of Medical Sciences
IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer
08/21
12/22
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer

Terminated
3
29
RoW
Oxaliplatin plus S-1, SOX, S-1 only, S-1
Peking University Cancer Hospital & Institute
Gastric Cancer
09/21
09/21
NCT03978364: A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

Recruiting
3
100
RoW
Azacitidine combined HHT, Azacitidine+HHT, Azacitidine regimen, Azacitidine group
Shandong Provincial Hospital
Myelodysplastic Syndromes,Acute Myeloid Leukemia
06/22
12/22
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
3
160
RoW
Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX
Shandong Provincial Hospital
High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma
12/23
12/24
NCT05097443: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
3
130
RoW
Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
Shandong Provincial Hospital
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma
12/23
12/24
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
07/24
10/24
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Recruiting
3
150
RoW
Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B Cell Lymphoma (DLBCL)
07/24
12/25
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Recruiting
3
218
RoW
ICP-022, Chlorambucil, Rituximab
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
06/25
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting
3
356
RoW
Orelabrutinib and R-CHOP, R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Treatment-naїve Mantle Cell Lymphoma
12/24
12/27
NCT04821843: Neoadjuvant Treatment Modalities in Esophageal Cancer

Recruiting
3
2000
RoW
Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay, Surgery, Immunotherapy, 5-FU Analog based chemotherpay, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric Juction Cancer
12/25
12/25
NCT04821778: Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Recruiting
3
2000
RoW
Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy, Immunotherapy, 5-FU Analog based chemotherapy, Nimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect
12/25
12/25
NCT05406882: The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis

Recruiting
2/3
176
RoW
Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules, Probiotics、Glutamine
West China Hospital
Radiation Proctitis, Probiotics, Glutamine, Gut Microbiota, Bifidobacterium
04/24
09/24
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Completed
2
55
RoW
Radiotherapy, Nimotuzumab, S-1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm
12/22
06/23
Rvision-001, NCT04147728: Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC

Recruiting
2
50
RoW
Anlotinib, Antiangiogenic agents, Stereotactic Radiosurgery
Peking University Third Hospital, Huashan Hospital, Tianjin Medical University
Stereotactic Body Radiation Therapy
12/21
12/22
NCT04547452: Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC

Recruiting
2
84
RoW
Stereotactic body radiation therapy, SBRT, Anti-PD-1 antibody drug named Sintilimab
West China Hospital
Stage IV HCC, Immunotherapy, SBRT
07/22
07/23
NCT06410651: Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Recruiting
2
53
RoW
Nimotuzumab with chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy
12/25
12/26
NCT06429839: Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Recruiting
2
55
RoW
Nimotuzumab with chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy
12/25
12/26
AK104-RC48 UC 01, NCT06178601: A Study of RC48-ADC Combined With Cadonilimab(AK104)in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
2
36
RoW
RC48-ADC, AK104
Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Urothelial Carcinoma
09/24
04/26
NCT04821765: Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Recruiting
2
35
RoW
PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel, Cisplatin
Chinese Academy of Medical Sciences
Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease, Immunotherapy
09/23
09/23
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Recruiting
2
240
RoW
Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight
Suzhou Alphamab Co., Ltd.
Knee Arthroplasty, Total
12/25
04/26
POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

Recruiting
2
186
RoW
Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)
Beijing Friendship Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, BeiGene
Locally Advanced Rectal Cancer
03/24
09/29
NCT06334367: Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

Not yet recruiting
2
40
RoW
CD25 treatment, low-dose ATG
Wang Xin
GVHD
03/26
03/26
NEXUS-2, NCT06430658: Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

Recruiting
2
90
RoW
Tislelizumab (BGB-A317) with chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophagus Cancer
12/26
12/27
NCT06421376: Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

Recruiting
2
60
RoW
Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy, Surgery
12/26
12/27
NCT05490485: Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
2
20
RoW
Camrelizumab, cisplatin
Henan Cancer Hospital
Squamous Cell Carcinoma of the Skin
07/24
07/24
NCT06637007: Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Recruiting
2
30
RoW
Chidamide Tablets combined with AK112, AK112
Shanxi Province Cancer Hospital
Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone
12/24
12/24
NCT06074484: A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Recruiting
2
36
RoW
RC48-ADC, Disitamab Vedotin, AK104, Cadonilimab Injection
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital
Muscle Invasive Bladder Carcinoma
08/24
08/25
NCT06642545: Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Recruiting
2
40
RoW
Disitamab Vedotin, RC48, RC148, Albumin-bound Paclitaxone, Toripalimab, JS001
RemeGen Co., Ltd.
Breast Cancer
10/26
10/27
NCT05430737: A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer

Recruiting
2
60
RoW
stereotactic body radiotherapy
West China Hospital
Prostate Cancer, Stereotactic Body Radiotherapy, High-risk, Efficacy, Safety
06/25
06/25
NCT06123455: Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer

Recruiting
2
60
RoW
Taurine, Sintilimab, XELOX regimen, SOX regimen, FOLFOX regimen
Tang-Du Hospital
Gastric Cancer
07/25
07/25
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Recruiting
2
78
RoW
Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum
The First Affiliated Hospital of Soochow University
Non-GCB/ABC Diffuse Large B-Cell Lymphoma
10/25
10/25
NCT04278287: Chemoradiotherapy in Unresectable Esophageal Cancer

Recruiting
1/2
105
RoW
Radiotherapy, Albumin-Bound Paclitaxel, Nab-Paclitaxel, Cisplatin, platinum
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
12/25
12/26
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Recruiting
1/2
170
RoW
Lenvatinib + Envafolimab, Sunitinib
3D Medicines (Sichuan) Co., Ltd.
Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
12/24
12/24
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

Recruiting
1/2
218
RoW
ABO2011 Injection, ABO2011, ABOD2011, Toripalimab
Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd
Solid Tumor, Adult
12/26
12/27
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome

Recruiting
1/2
60
RoW
STSA-1002 Injection Placebo, STSA-1002 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Acute Respiratory Distress Syndrome
08/25
09/26
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting
1
156
RoW
HSK29116
Haisco Pharmaceutical Group Co., Ltd.
Relapsed/Refractory B-Cell Malignancies
08/23
10/23
NCT06024915: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Not yet recruiting
1
40
RoW
TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
10/23
12/23
NCT06167486: SG2918 For Advanced Malignant Tumors

Recruiting
1
117
RoW
SG2918
Hangzhou Sumgen Biotech Co., Ltd.
Advanced Malignant Tumors
12/25
12/26
NCT06344936: Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects

Not yet recruiting
1
28
RoW
HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
Shandong Suncadia Medicine Co., Ltd.
Chronic Kidney Disease(CKD)
07/24
07/24
NCT02988921: MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy

Recruiting
N/A
300
RoW
MRI and CT, Ratiotherapy, Paclitaxel, platinum-based drug
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophagus Cancer, Esophagogastric Junction Cancer
01/25
12/26
NCT03247764: A Registration Study on Depression in Patients With Epilepsy

Recruiting
N/A
320
RoW
Shanghai Zhongshan Hospital
Epilepsy, Depression
12/21
01/22
NCT03902041: The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT

Not yet recruiting
N/A
160
RoW
Eltrombopag
Shandong Provincial Hospital
Allogeneic Hematopoietic Stem Cell Transplantation, Eltrombopag
04/22
10/22
DCB-denovo, NCT04022200: Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions

Recruiting
N/A
300
RoW
Paclitaxel DCB
Beijing Hospital
Coronary Disease
01/23
07/23
NCT06347965: Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy

Completed
N/A
104
RoW
Low load blood flow restriction training, Progressive resistance training group
Xin Wang
Sarcopenia, Lung Neoplasms
11/23
02/24
NCT06391788: Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy

Recruiting
N/A
132
RoW
thoracoscopic Morrow surgery, modified Morrow surgery
China National Center for Cardiovascular Diseases
Cardiomyopathy, Hypertrophic Obstructive, Minimally Invasive Surgery
02/25
03/25
NCT04502628: Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT

Recruiting
N/A
150
RoW
Hyperbaric oxygen therapy
Shandong Provincial Hospital
Stem Cell Transplant Complications
07/23
12/24
REALM, NCT05506774: A Study of People With CD30 Positive Lymphoma in China

Completed
N/A
1006
RoW
Takeda
Lymphoma
07/24
07/24
NCT04664439: Follow-up With CT-FFR in CHD Patients After DCB

Recruiting
N/A
92
RoW
CT-FFR
Beijing Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
Coronary; Ischemic
12/23
06/24
NCT05723731: Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation

Terminated
N/A
106
RoW
taVNS, Laxative Agent
Air Force Military Medical University, China
Chronic Constipation
07/23
09/23
NCT05718778: Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma

Recruiting
N/A
31
RoW
Piamprimab (AK105), radiotherapy
Henan Cancer Hospital
Soft Tissue Sarcoma
03/24
03/24
CLL2023, NCT05920668: Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

Recruiting
N/A
20
RoW
Orelabrutinib
Wang Xin
CLL/SLL
07/24
07/25
NCT06128252: Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

Recruiting
N/A
96
RoW
Taurine, Serplulimab, XELOX regimen, Placebo
Tang-Du Hospital
Gastric Cancer
06/26
06/26
NCT05934864: Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)

Recruiting
N/A
1000
RoW
84-gene penal
Ruijin Hospital, West China Hospital, Shandong Provincial Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Institute and Hospital
Peripheral T Cell Lymphoma
06/25
06/26
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
NCT04874493: Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer

Active, not recruiting
N/A
77
US
Electronic Health Record Review, Questionnaire Administration
M.D. Anderson Cancer Center
Oropharyngeal Carcinoma
02/27
02/27
NCT00505245: New Assessment System in Measuring Symptom Distress in Cancer Patients

Recruiting
N/A
6500
US
Interview, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, National Institutes of Health (NIH)
Caregiver, Health Care Provider, Malignant Neoplasm, Physician
04/31
04/31
NCT05628480: Multi-omics Analyses Reveal Microbiota-gut-brain Axis in ICU Patients With Post-cardiac Surgery Delirium

Completed
N/A
60
RoW
China National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences
Postoperative Delirium, Cardiac Disease, Gastrointestinal Microbiome
10/23
10/23
LU, Zhiyong
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Recruiting
1/2
170
RoW
Lenvatinib + Envafolimab, Sunitinib
3D Medicines (Sichuan) Co., Ltd.
Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
12/24
12/24

Download Options